Covid-19 vaccination: What’s the evidence for extending the dosing interval?

  title={Covid-19 vaccination: What’s the evidence for extending the dosing interval?},
  author={Gareth Iacobucci and Elisabeth Mahase},
On 30 December the four UK chief medical officers announced that the second doses of the covid vaccines should be given towards the end of 12 weeks rather than in the previously recommended 3-4 weeks. Gareth Iacobucci and Elisabeth Mahase look at the questions this has raised 

COVID-19 vaccines for low- and middle-income countries

  • E. M. Choi
  • Economics
    Transactions of the Royal Society of Tropical Medicine and Hygiene
  • 2021
How low- and middle-income countries access COVID-19 vaccines, what is being done to distribute vaccines fairly, as well as the challenges ahead are described.

COVID-19 vaccination challenges: A mini-review

The different recommendations and guidelines regarding the time interval between the two vaccine doses are discussed and it is explained the different scenarios for applying the two doses.

COVID-19 vaccination: Recommendations for management of patients with allergy or immune-based diseases.

  • J. Peter
  • Medicine
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde
  • 2021
This practice guideline offers broad recommendations for COVID-19 vaccination in various subgroups of allergic and immunebased disease, highlighting risk/benefit evaluation, and where and how routine vaccination should be altered.

Interim Estimates of COVID-19 Vaccine Effectiveness in a Mass Vaccination Setting: Data from an Italian Province

Findings support current immunization policies and may help reducing vaccine hesitancy, as the effectiveness of either BNT162b2, ChAdOx1 nCoV-19 or mRNA-1273 vaccines was higher than 95% in preventing infections, symptomatic or lethal COVID-19.

Covid-19: Longer interval between Pfizer doses results in higher antibody levels, research finds

It is found that the long dosing interval gives rise to T cells which are more typical of helper T cells and long term memory T cells that promote memory and generation of antibodies.

Should We Delay the Second COVID-19 Vaccine Dose in Order to Optimize Rollout? A Mathematical Perspective

The results suggest that although extending the interval between doses beyond 12 weeks was likely optimal earlier in the pandemic, the reduced single dose efficacy of vaccines against the delta variant make this approach no longer viable.

Investigating the uptake, effectiveness and safety of COVID-19 vaccines: protocol for an observational study using linked UK national data

This study aims to assess the uptake rates, effectiveness, and safety of all currently approved COVID-19 vaccines in the UK and uses prospective cohort study designs to assess vaccine uptake, effectiveness and safety against clinical outcomes and deaths.

Application of quantitative systems pharmacology to guide the optimal dosing of COVID‐19 vaccines

Here, it is proposed for the first time how QSP can be applied in the context of Covid-19 vaccine development and how it is well placed to guide such extrapolation in a rational and timely manner.

May we overcome the current serious limitations for distributing reconstituted mRNA vaccines?

There is an urgent need to ameliorate the transport of the reconstituted vaccines to the vaccination sites to improve the COVID-19 vaccination campaigns. The maintenance of the integrity of the mRNA